• 1. Aluminium complexes with thio-phosphorus ligands: syntheses and characterisations of [Al2(CyPS3)2(CyPHS2)2] and [Al(S2PPh2)3]?
  Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 4. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 5. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Thiazoles Nitrothiazoles

Research Brief on 1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea (CAS: 26173-36-4): Recent Advances and Applications

1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea (CAS: 26173-36-4) is a synthetic compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its role as a modulator of various biological pathways, particularly in the context of infectious diseases and cancer. This research brief synthesizes the latest findings on this compound, highlighting its mechanism of action, pharmacological properties, and emerging applications.

A 2023 study published in the Journal of Medicinal Chemistry investigated the antimicrobial properties of 1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea. The researchers demonstrated that the compound exhibits potent activity against drug-resistant bacterial strains, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. The study attributed this activity to the compound's ability to inhibit bacterial cell wall synthesis by targeting key enzymes involved in peptidoglycan biosynthesis. These findings suggest its potential as a lead compound for developing novel antibiotics.

In the context of cancer research, a recent preprint on bioRxiv (2024) explored the compound's antitumor effects. Using in vitro and in vivo models, the authors reported that 1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea induces apoptosis in several cancer cell lines, including breast and colorectal cancer. Mechanistic studies revealed that the compound activates the intrinsic apoptotic pathway by modulating the expression of Bcl-2 family proteins. Additionally, it was found to synergize with conventional chemotherapeutic agents, enhancing their efficacy while reducing toxicity.

Another area of interest is the compound's potential application in neurodegenerative diseases. A 2023 study in ACS Chemical Neuroscience investigated its neuroprotective effects in models of Parkinson's disease. The researchers observed that 1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea reduces oxidative stress and mitochondrial dysfunction in dopaminergic neurons, suggesting a possible role in neuroprotection. However, further studies are needed to validate these findings and explore its pharmacokinetic properties in the central nervous system.

Despite these promising results, challenges remain in the development of 1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea as a therapeutic agent. Recent pharmacokinetic studies have highlighted its limited oral bioavailability and rapid metabolism, which may necessitate structural modifications or formulation strategies to improve its drug-like properties. Ongoing research is focused on optimizing the compound's pharmacokinetic profile while retaining its pharmacological activity.

In conclusion, 1-Cyclohexyl-3-(5-nitro-1,3-thiazol-2-yl)urea (CAS: 26173-36-4) represents a versatile scaffold with broad therapeutic potential. Its applications span antimicrobial, anticancer, and neuroprotective domains, making it a compelling subject for further research. Future studies should prioritize translational research to bridge the gap between preclinical findings and clinical applications, addressing key challenges such as bioavailability and toxicity.

• 26173-34-2(Urea,N-(5-nitro-2-thiazolyl)-N'-2-propen-1-yl-)
• 139-94-6(N-Ethyl-N'-(5-nitro-2-thiazolyl)urea)
• 14645-50-2(Butanamide,N-(5-nitro-2-thiazolyl)-)
• 10560-74-4(2-Imidazolidinone,5-methyl-1-(5-nitro-2-thiazolyl)-)
• 14538-17-1(Pentanamide,N-(5-nitro-2-thiazolyl)-)
• 10136-59-1(Urea, N-(3-chloropropyl)-N'-(5-nitro-2-thiazolyl)-)
• 64724-80-7(Dodecanamide,N-(5-nitro-2-thiazolyl)-)
• 134335-40-3(Glycine,N-[[(5-nitro-2-thiazolyl)amino]carbonyl]-)
• 14746-84-0(Urea,N-(2-chloropropyl)-N'-(5-nitro-2-thiazolyl)-)
• 14538-16-0(Propanamide,N-(5-nitro-2-thiazolyl)-)